Great West Life Assurance Co. Can trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating) by 5.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 433,548 shares of the company's stock after selling 23,727 shares during the quarter. Great West Life Assurance Co. Can's holdings in Teva Pharmaceutical Industries were worth $3,490,000 as of its most recent filing with the SEC.
Other hedge funds have also bought and sold shares of the company. Private Trust Co. NA bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $32,000. Credit Agricole S A bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $34,000. Newbridge Financial Services Group Inc. increased its position in Teva Pharmaceutical Industries by 555.6% during the third quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company's stock worth $48,000 after acquiring an additional 5,000 shares during the period. Ritholtz Wealth Management bought a new position in Teva Pharmaceutical Industries during the third quarter worth about $85,000. Finally, MQS Management LLC bought a new position in Teva Pharmaceutical Industries during the second quarter worth about $89,000. 50.39% of the stock is owned by institutional investors.
Get Teva Pharmaceutical Industries alerts:Teva Pharmaceutical Industries Trading Down 0.3 %
Shares of Teva Pharmaceutical Industries stock opened at $10.38 on Tuesday. The firm has a market capitalization of $11.53 billion, a PE ratio of -8.95 and a beta of 1.19. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. The firm's 50 day moving average is $9.40 and its 200 day moving average is $9.02. Teva Pharmaceutical Industries Limited has a 1 year low of $6.78 and a 1 year high of $11.44.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last posted its earnings results on Thursday, November 3rd. The company reported $0.56 EPS for the quarter, missing the consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The business had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.86 billion. Equities research analysts forecast that Teva Pharmaceutical Industries Limited will post 2.4 earnings per share for the current fiscal year.Analyst Upgrades and Downgrades
Several equities analysts have commented on TEVA shares. JPMorgan Chase & Co. lowered shares of Teva Pharmaceutical Industries from a "neutral" rating to an "underweight" rating and decreased their target price for the company from $11.00 to $10.00 in a report on Monday, November 14th. StockNews.com started coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 12th. They issued a "buy" rating on the stock. Piper Sandler decreased their target price on shares of Teva Pharmaceutical Industries from $8.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, November 23rd. UBS Group lowered shares of Teva Pharmaceutical Industries from a "neutral" rating to a "sell" rating in a report on Friday, November 4th. Finally, BMO Capital Markets decreased their target price on shares of Teva Pharmaceutical Industries from $11.00 to $10.00 and set a "market perform" rating on the stock in a report on Monday, November 7th. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $10.67.
Teva Pharmaceutical Industries Profile
(Get Rating)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Further Reading
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft's Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA – Get Rating).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.